Obstructive sleep apnea is a sleep-related breathing disorder in which recurrent upper-airway collapse during sleep causes intermittent airflow reduction or cessation, fragmented sleep, and cardiometabolic risk.
Amgen shares have fallen 12.6% in three months despite relatively solid Q1 results, while Novo Nordisk maintains a 54.6% global GLP-1 market share. Both companies face pipeline competition and pricing pressures.
Q1 2026 sleep medicine trends include broader use of AI, expanding obstructive sleep apnea and narcolepsy treatments, and policy changes affecting reimbursement and access.
A study of over 600,000 patients reveals GLP-1 drugs may reduce addiction across multiple substances, with 50% fewer substance-related deaths and significant reductions in overdoses and hospitalizations. The drugs work by dampening dopamine signaling in brain reward centers. Researchers are exploring broader applications for these medications beyond diabetes and obesity treatment.
Eli Lilly's orforglipron demonstrated superior A1C reduction and weight loss compared to oral semaglutide in the ACHIEVE-3 trial, with regulatory submissions filed in over 40 countries and a potential US decision expected in Q2 2026.
Children with obstructive sleep apnea face nearly twice the risk of contracting influenza or COVID-19 compared to controls, with increased vulnerability persisting even after adenotonsillectomy, according to a five-year study of over 1 million children.
Eli Lilly is developing multiple next-generation obesity treatments, including oral GLP-1 drug orforglipron expected to launch in Q2 2026, as competition intensifies in a market projected to reach $95 billion by 2030.
UK and Brazil issue warnings about possible pancreatitis link to GLP-1 weight-loss drugs, while WADA monitors their use in Olympic athletes amid concerns about muscle loss and performance effects.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07753785 |
Oliceridine Versus Sufentanil Analgesia for Postoperative Patients With Obstructive Sleep Apnea |
NOT_YET_RECRUITING | |
| NCT07724938 |
Combination Tonsillectomy and Hypoglossal Nerve Stimulation for OSA Patients With Lateral Pharyngeal Collapse |
NOT_YET_RECRUITING | NA |
| NCT07723417 |
DISE vs Muller's Maneuver in OSA Assessment |
COMPLETED | NA |
| NCT07723144 |
Identification of Biomarkers of Obstructive Sleep Apnea. |
RECRUITING | NA |
| NCT07716995 |
Association Between Metabolic Associated Fatty Liver Disease and Obstructive Sleep Apnea |
NOT_YET_RECRUITING | |
| NCT07678918 |
Cognitive Function and Quality of Life in Obstructive Sleep Apnea |
NOT_YET_RECRUITING | |
| NCT07669870 |
LOW LEVEL LASER THERAPY VS EXERCISES FOR SNORING IN SLEEP APNEA 'S PATIENTS |
COMPLETED | NA |
| NCT07658053 |
Effects of a Pacifier on Obstructive Sleep Apnea and Its Repercussions in Infants With Down Syndrome |
NOT_YET_RECRUITING | NA |
| NCT07622745 |
Nasal Surgery in Snoring and Obstructive Sleep Apnea |
COMPLETED | NA |
| NCT07603583 |
Assessment of Heart Rate Variability for Predicting Obstructive Sleep Apnea in Patients With Hypertension |
RECRUITING |
